Shots:

• The approval is based on the P-III RHAPSODY trial involves assessing Arcalyst (SC- qw- 300mg followed by 160mg) vs PBO in adults and children aged ≥12yrs. in a ratio (1:1) with recurrent pericarditis
• The result showed a 96% reduction in the risk- with pain- free or minimal pain days (92% vs 40%)- sustained reductions in both reported pain and inflammation as early as the first dose & improvement in clinical outcomes
• Arcalys (rilonacept) is a recombinant dimeric fusion protein that blocks IL-1α and IL-1β signaling and is expected to be available in Apr’21. Additionally- the company launches the One Connect patient support program to assess patients on their treatment journey

 ­ Ref: GlobeNewswire | Image: Kiniksa